Steve Pacelli Appointed CEO of Epitel, Inc.

Pacelli, A Former Executive of Dexcom, Inc., Will Lead Epitel Into Its Next Phase of Growth

Steve Pacelli Appointed CEO of Epitel, Inc.

Media Contact
Maya Villanueva
Vuturo Group for Epitel
(415) 689-8414
epitel@vuturo.com

Epitel, Inc., a leader in AI technologies for patient-focused brain health solutions, is pleased to announce that Steve Pacelli has been appointed as the company's new Chief Executive Officer. Pacelli, a seasoned executive with a track record of success in the medical technology industry, brings a wealth of experience and leadership to Epitel as it further drives its mission to transform the lives of individuals affected by seizures and other neurological conditions. As the executive team expands, Mark Lehmkuhle, the company’s current CEO and founder, will transition to the role of Chief Technology Officer.

“Mark has been the driving force behind Epitel since its inception,” said Pacelli. “His vision, energy and dedication have been instrumental in building the company and defining its incredible culture. Mark will continue to play a vital role as we move forward, now with a sharper focus on leading our technological vision and ensuring that innovation is at the forefront of our product development.”

Prior to joining Epitel, Pacelli served in numerous operating roles throughout his nearly twenty-year tenure at Dexcom, where he played a pivotal role in the company's growth and success, helping to expand its leadership in the diabetes management market. Pacelli’s expertise in scaling groundbreaking technologies, forging strategic partnerships, and driving operational excellence makes him uniquely qualified to lead Epitel into its next phase of growth.

“I am thrilled to join Epitel at this exciting time in the company’s journey,” continued Pacelli. “Epitel’s vision for improving the lives of individuals with neurological conditions through continuous, non-invasive brain health monitoring is inspiring. I look forward to working with the talented team at Epitel to accelerate our efforts in advancing healthcare solutions and delivering meaningful outcomes for patients.”

“As Epitel grows, so do the demands of managing our organization and ambition. Steve’s passion for patient-centered innovation and strategic vision make him the ideal leader to guide us and I am confident that Steve will propel Epitel into our next chapter of success,” said Lehmkuhle.

Epitel, which specializes in wearable, wireless, and non-invasive EEG technology, has made significant strides in the development of the REMI portfolio, an AI-enabled seizure monitoring platform. With a mission to make EEG more accessible and equitable, the company is poised for continued growth and innovation under Pacelli’s leadership.

“Steve is an exceptional leader with a proven ability to execute,” said Joshua Phillips, Chairman of Epitel's Board of Directors and Managing Partner at Catalyst Health Ventures, an early investor in the company. “We are at a pivotal stage in our growth, and it’s clear that we need to scale our commercial presence to meet the opportunities that lie ahead.”

About Epitel, Inc.

Epitel™ is a digital health company modernizing brain health solutions. By leveraging a proprietary cloud-based wearable sensor system and other innovative AI technologies, Epitel is empowering more informed treatment decisions by making EEG readily deployable and accessible with an initial focus on improving seizure monitoring and detection. Visit www.epitel.com to learn more.